Clinical stage biopharmaceutical company Clementia Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its palovarotene to treat fibrodysplasia ossificans progressive (FOP).

Clementia chief development officer Jeff Packman said: "Following the recent initiation of our Phase II clinical study, we are pleased to receive orphan drug designation for palovarotene and believe this represents an important regulatory milestone for our development programme."

The company initiated the Phase II clinical trial of palovarotene, a retinoic acid receptor gamma agonist, on 14 July.

"Following the recent initiation of our Phase II clinical study, we are pleased to receive orphan drug designation for palovarotene and believe this represents an important regulatory milestone for our development programme."

The double-blind, placebo-controlled clinical trial will assess the effect of different doses of palovarotene on new bone formation during and after a flare-up in 24 FOP patients who are 15 years of age or older.

A number of clinical endpoints will assess the efficacy and safety of palovarotene, including imaging endpoints for new bone formation and clinical assessments of physical function and patient-reported outcomes.

Palovarotene has been shown to block bone formation in a variety of mouse models of heterotopic ossification. The Phase II clinical trial has been designed to determine whether the effects seen in these mouse models could be recapitulated in FOP patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company anticipates completing the clinical trial during 2015.

Palovarotene has been in-licensed from Roche in 2013 where the drug was previously evaluated in more than 800 individuals, including healthy volunteers and patients with chronic obstructive pulmonary disease.